Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Valrubicin in BCG-Refractory Bladder CIS
NCT01316874Phase 3Completed
- Sponsor
- Endo International plc
- Start
- Nov 1993
- Primary completion
- Apr 1997
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of valrubicin in bladder carcinoma in situ (CIS), sponsored by Endo International plc. Primary endpoint: Efficacy of AD 32 (valrubicin) at 12 weeks. Started Nov 1993; status: completed.
02
Drugs
valrubicin
03
Conditions
bladder carcinoma in situ (CIS)
Beyond the preview
Go deeper on NCT01316874.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01316874.